MedPath

AstraZeneca

AstraZeneca logo
🇬🇧United Kingdom
Ownership
Public
Employees
89.9K
Market Cap
$270.3B
Website
http://www.astrazeneca.co.uk
Introduction

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

Phase 3
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2007-01-11
Last Posted Date
2009-03-27
Lead Sponsor
AstraZeneca
Target Recruit Count
315
Registration Number
NCT00421122
Locations
🇨🇳

Research Site, Hangzhou, Zhejiang, China

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Budesonide/formoterol (SYMBICORT) pMDI
Drug: Budesonide HFA pMDI
First Posted Date
2007-01-09
Last Posted Date
2012-10-30
Lead Sponsor
AstraZeneca
Target Recruit Count
742
Registration Number
NCT00419952
Locations
🇺🇸

Research Site, Springfield, Virginia, United States

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Budesonide HFA pMDI
Drug: Budesonide/formoterol (SYMBICORT) pMDI
First Posted Date
2007-01-09
Last Posted Date
2012-08-27
Lead Sponsor
AstraZeneca
Target Recruit Count
558
Registration Number
NCT00419757
Locations
🇵🇷

Research Site, Trujillo Alto, Puerto Rico

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

Phase 3
Completed
Conditions
Chronic Obstructive Pulmonary Disease
First Posted Date
2007-01-09
Last Posted Date
2010-09-16
Lead Sponsor
AstraZeneca
Target Recruit Count
1200
Registration Number
NCT00419744
Locations
🇻🇪

Research Site, Distrito Capital, Caracas, Venezuela

Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: AZD7762
Drug: Gemcitabine
First Posted Date
2006-12-20
Last Posted Date
2010-12-06
Lead Sponsor
AstraZeneca
Target Recruit Count
42
Registration Number
NCT00413686
Locations
🇺🇸

Research Site, Detroit, Michigan, United States

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

Phase 4
Completed
Conditions
Gastroesophageal Reflux Disease
First Posted Date
2006-12-13
Last Posted Date
2009-03-11
Lead Sponsor
AstraZeneca
Target Recruit Count
90
Registration Number
NCT00410592
Locations
🇵🇷

Research Site, San Juan, Puerto Rico

🇺🇸

Research SIte, Chapel Hill, North Carolina, United States

Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: Ciclesonide
Drug: Usual Care Inhaled Glucocorticosteroids
First Posted Date
2006-11-28
Last Posted Date
2017-02-01
Lead Sponsor
AstraZeneca
Target Recruit Count
1121
Registration Number
NCT00404547
Locations
🇨🇦

"Altana Pharma/Nycomed", York, Canada

Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding

Phase 3
Completed
Conditions
Gastrointestinal Hemorrhage
First Posted Date
2006-11-22
Last Posted Date
2009-03-12
Lead Sponsor
AstraZeneca
Target Recruit Count
440
Registration Number
NCT00402259
Locations
🇨🇳

Research Site, Tianjin, China

🇨🇳

Research site, Fuzhou, Fujian, China

Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer

Phase 3
Completed
Conditions
Gastric Ulcer
First Posted Date
2006-11-22
Last Posted Date
2010-07-08
Lead Sponsor
AstraZeneca
Target Recruit Count
397
Registration Number
NCT00401752
Locations
🇭🇰

Research Site, Hong Kong, Hong Kong

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Phase 2
Completed
Conditions
Overweight
Obesity
Interventions
First Posted Date
2006-11-22
Last Posted Date
2015-03-06
Lead Sponsor
AstraZeneca
Target Recruit Count
258
Registration Number
NCT00402077
Locations
🇺🇸

Research Site, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath